Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Glofitamab combined with salvage therapy for relapsed or refractory aggressive B-cell lymphomas: Efficacy and safety in a real-world prospective observational study

View Full Paper
Ask AI
Bookmark
Share

Authors

TYTao YouHHHaiwen Huang

Discussion

Loading...

Member takes

Overview

Observational analysis found a 60.75% one-year progression-free survival in patients with R/R aggressive B-cell lymphomas, indicating favorable outcomes with glofitamab and salvage therapy.

Key Points

  • The overall response rate and one-year progression-free survival were significantly improved compared to previous findings.
  • Among 66 patients evaluated, the median age was 54 years, with the majority exhibiting aggressive B-cell lymphomas.
  • A combination of glofitamab and standard salvage therapies were used, with various regimens yielding similar safety profiles.
  • Effective monitoring for cytokine release syndrome and infections is essential for managing treatment in this challenging population.

Cite This Study

You et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236dfcbhttps://doi.org/10.1182/blood-2025-7267
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world outcomes of glofitamab-based regimens in relapsed/refractory aggressive B-cell lymphoma2025
  2. 2Real-world efficacy, safety, and predictive factors for response to glofitamab in Chinese patients with relapsed/refractory aggressive B-cell lymphoma: A multicenter study2025
  3. 3Therapeutic outcomes of glofitamab-based regimens in Chinese patients with Relapsed/Refractory B-cell lymphoma: A single-center retrospective real-world study2025
  4. 4Real-world outcomes of glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) in Relapsed/Refractory (R/R) aggressive B-cell lymphoma (BCL): A multicenter retrospective study from the United States2025
  5. 5Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO2025